Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene
E. Antonio Chiocca, Hiroshi Nakashima, Kazue Kasai, Soledad Fernández, Michael Oglesbee
Abstract
toxicity of rQNestin34.5v.2 was compared with that of wild-type F strain in immunocompetent BALB/c mice and athymic mice by multiple routes of administration in the presence or absence of CPA. A likely no observed adverse effect level (NOAEL) dose for intracranial rQNestin34.5v.2 was estimated, justifying a phase 1 clinical trial in recurrent glioma patients (ClinicalTrials.gov: NCT03152318), after successful submission of an IND.
Topics & Concepts
Oncolytic virusVirologyBiologyGeneMedicineVirusGeneticsVirus-based gene therapy researchHerpesvirus Infections and TreatmentsViral Infectious Diseases and Gene Expression in Insects